Because concurrent treatment with PD dopaminergic therapies, especially MAO-B inhibitors, can affect dopamine metabolites16 and thereby confound the results, our analysis controlled for the dose and change in the dopaminergic therapy. The gene discussed is MAOB; the disease is Parkinson disease.